Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Drospirenone

FDA-approved product (tablet, oral), marketed as Drospirenone, Slynd.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Drospirenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Progestogens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Drospirenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Drospirenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety Oral Contraceptive Study

    NCT00185484 · start 2004-03

    Registered record
    Registry ID
    NCT00185484
    Conditions
    Contraception
    Interventions
    YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-03
    Completion
    2006-01
    Enrolment
    1,113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionYAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

    NCT00185419 · start 2003-11

    Registered record
    Registry ID
    NCT00185419
    Conditions
    Contraception
    Interventions
    Yasmin; Marvelon
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2006-03
    Enrolment
    842

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionYasmin; Marvelon
    PhasePhase 3
    Registry statusCompleted

  • Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women

    NCT00651846 · start 2003-06

    Registered record
    Registry ID
    NCT00651846
    Conditions
    Healthy
    Interventions
    Yasmin (DRSP 3mg/EE 0.03 mg); Microgynon (LNG 0.15 mg/EE 0.03 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-06
    Completion
    2005-02
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionYasmin (DRSP 3mg/EE 0.03 mg); Microgynon (LNG 0.15 mg/EE 0.03 mg)
    PhasePhase 4
    Registry statusCompleted

  • European Active Surveillance Study (EURAS)

    NCT00302848 · start 2000-11

    Registered record
    Registry ID
    NCT00302848
    Conditions
    Contraception
    Interventions
    Drospirenone; Levonorgestrel; Other progestin containing oral contraceptive
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-11
    Completion
    2005-12
    Enrolment
    59,510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionDrospirenone; Levonorgestrel; Other progestin containing oral contraceptive
    PhaseNot recorded
    Registry statusCompleted

  • Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance

    NCT01511822

    Registered record
    Registry ID
    NCT01511822
    Conditions
    PCOS; Polycystic Ovary Syndrome
    Interventions
    Drospirenone Ethinyl estradiol; Drospirenone Ethinyl estradiol Myo-inositol; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS; Polycystic Ovary Syndrome
    InterventionDrospirenone Ethinyl estradiol; Drospirenone Ethinyl estradiol Myo-inositol; placebo
    PhasePhase 4
    Registry statusCompleted